BBBernd Brüggenjürgen

Bernd Brüggenjürgen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernd Brüggenjürgen has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Christina Stukenborg-Colsman

    Foot Department, Orthopedic Department - Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital, Hannover, Germany

    3 shared publications
  • Thomas Reinhold

    Institute for Social Medicine, Epidemiology, and Health Economics, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

    3 shared publications
  • Andreas Kannenberg

    Otto Bock Healthcare LP, Austin, Texas, USA

    2 shared publications
  • Christian Vogelberg

    Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus Technical University Dresden Dresden Germany

    2 shared publications
  • Ludger Klimek

    Department of Otolaryngology, Head and Neck Surgery Universitätsmedizin Mainz Mainz Germany

    2 shared publications
  • Marek Jutel

    Department of Clinical Immunology, Faculty of Medicine Wroclaw Medical University Wroclaw Poland

    2 shared publications

Latest Publications

  • Open Access

    HEALTH-RELATED QUALITY OF LIFE IN AMPUTEES WITH A MICROPROCESSOR-CONTROLLED PROSTHETIC KNEE MEASURED BY THE EQ-5D-5L

    by Bernd Brüggenjürgen, Andreas Kannenberg, Christina Stukenborg-Colsman, Andreas Hahn

    BACKGROUND: Enhancing health-related quality of life (HRQoL) is a fundamental objective of healthcare delivery. Individuals with amputation might encounter physical, psychological, and social challenges in daily life which might be influenced by the type of prosthetic knee provided. OBJECTIVE: To understand the experience-based HRQoL of amputees who were using a microprocessor-controlled prosthetic knee (MPK). METHODOLOGY: Amputees using an MPK for at least 3 months (C-Leg or Genium/Genium X3) participated in an online survey. In 2022 1,868 MPK user were invited to participate in the study via both desktop and mobile platforms of a German manufacturer database. HRQoL was assessed with the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument. The data was analyzed descriptively and by measures of central tendency. FINDINGS: 512 participants (19.7% female, mean age 54 years (standard deviation 12.6)) responded and fully completed the EQ-5D-5L. The leading cause of amputation was trauma (56.1%), followed by tumor (15.6%) and peripheral arterial disease (PAD, 11.3%). 18.2% reported being completely problem-free. 2.9% had a hip disarticulation, 68.0% a transfemoral amputation, 26.6% a knee disarticulation and 2.5% a bilateral amputation. The share of “no problems” was 53.3% for mobility, 88.1% for self-care, 61.5% for usual activities, 25.0% for pain or discomfort, and 67.4% for anxiety/depression. The total mean index score based on the German value set was 0.84 (maximum score 1). The total mean visual analogue scale (VAS) score was 77.4 with variations observed for age and health status. CONCLUSION: Amputees with an MPK experienced very few issues in the self-care dimension but faced more challenges in the pain/discomfort and mobility dimensions. Utilities were similar to the general German norm reporting one medical condition. MPKs enable individuals to achieve quality of life outcomes that are comparable to those observed in the general population. Layman's Abstract We wanted to learn how amputees who use a special prosthetic knee controlled by a microprocessor (“MPK”) in their prosthesis feel about their quality of life. In 2022, 1,868 people who use an MPK from a German manufacturer were invited to take part in an online survey. About one in five participants (19.7%) were women. Most respondents had an above-the-knee amputation (68.0%), while about a quarter had a knee disarticulation (26.6%). A small number had a hip disarticulation (2.9%) or amputations on both sides (2.5%). A tool known as the EQ-5D-5L was used to measure their quality of life. Answers were evaluated descriptively and to identify patterns. A total of 512 people with an average age around 54 years responded to the quality-of-life questionnaires. Most of them lost their limbs due to an accident. About 18% of them said they had no problems at all. The most common problems they faced were related to pain, discomfort, and mobility. On average, their quality-of-life score was 0.84 out of a maximum of 1, where 1 means perfect health. This score is similar to what people in Germany with one chronic medical condition typically report. People using an MPK generally have few problems taking care of themselves but struggle more with pain and moving around. Their overall quality of life is similar as that of the general German population. MPKs enable individuals to achieve quality of life outcomes that are comparable to those observed in the general population. Article PDF Link: https://jps.library.utoronto.ca/index.php/cpoj/article/view/46403/34874 How To Cite: Brüggenjürgen B, Kannenberg A, Stukenborg-Colsman C, Hahn A. Health-related quality of life in amputees with a microprocessor-controlled prosthetic knee measured by the EQ-5D-5L. Canadian Prosthetics & Orthotics Journal. 2026; Volume 9, Issue 1, No. 4. https://doi.org/10.33137/cpoj.v9i1.46403 Corresponding Author: Prof. Dr. med. Bernd Brüggenjürgen, MPHAffiliation: Institute for Health Services Research and Technical Orthopedics, Orthopedic Department - Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital, Hannover, Germany.E-Mail: brueggenjuergen.bernd@mh-hannover.deORCID ID: https://orcid.org/0000-0002-8866-0809

  • Open Access

    LETTER TO THE EDITOR REGARDING "HEALTH ECONOMIC EVALUATION OF MICROPROCESSOR AND NON-MICROPROCESSOR-CONTROLLED PROSTHETIC KNEES"

    by Bernd Brüggenjürgen, Annika Riemer, Matthias Gapp

    This Letter to the Editor responds to the article by Bosman et al. ( https://doi.org/10.33137/cpoj.v8i2.45823 ). Real-world Dutch resource use data from Bosman et al. demonstrated lower non-prosthesis healthcare costs for microprocessor-controlled knee users compared with non-microprocessor-controlled knees, although the reported incremental cost per QALY (€457,063) appears unexpectedly high. This estimate likely overstates cost per QALY because prosthesis-related expenses were inconsistently prorated and implicitly assumed a 6-month replacement cycle, which is not clinically plausible. Recalculation assuming a conservative 5-year prosthesis replacement cycle resulted in an ICUR of €19,603 per QALY, consistent with accepted health technology assessment thresholds. Article PDF Link: https://jps.library.utoronto.ca/index.php/cpoj/article/view/46339/34632 How To Cite: Brüggenjürgen B, Riemer A, Gapp M. Letter to the editor regarding "Health economic evaluation of microprocessor and non-microprocessor-controlled prosthetic knees". Canadian Prosthetics & Orthotics Journal. 2025; Volume 8, Issue 2, No. 6. Https://doi.org/10.33137/cpoj.v8i2.46339 Corresponding Author: Prof. Dr. med. Bernd Brüggenjürgen, MPHAffiliation: Institute for Health Services Research and Technical Orthopedics, Orthopedic Department, Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital, Germany.E-Mail: Brueggenjuergen.Bernd@mh-hannover.deORCID ID: https://orcid.org/0000-0002-8866-0809


  • Open Access

    PATIENTS’ BURDEN USING MICROPROCESSOR-STANCE-AND-SWING-CONTROL KNEE-ANKLE-FOOT ORTHOSES AND OUTCOMES COMPARED TO THOSE WITH PRIOR TRADITIONAL KNEE-ANKLE-FOOT-ORTHOSIS

    by Bernd Brüggenjürgen, Lena Eilers, Susanne Seidinger, Andreas Kannenberg, Christina Stukenborg-Colsman

    BACKGROUND: Patients with neuromuscular knee instability who are fitted with orthotic devices experience issues such as pain, falls, mobility limitations, and restricted participation. OBJECTIVES: To analyze the burden of disease in patients using a microprocessor-stance-and-swing-control orthosis (MP-SSCO) and, if they had a previous orthosis, to compare their outcomes to those with previous use of a traditional knee-ankle-foot-orthosis (KAFO) under real-world conditions. METHODOLOGY: A structured cross-sectional survey was conducted in six orthotic and prosthetic clinics in Germany. Individuals who had been using an MP-SSCO (C-Brace) for at least six months, answered an internet-based survey to rate their current and recall previous device outcomes and experience. The questionnaire was self-developed based on established questionnaire design principles and pretested. Patients' well-being dimensions were analyzed with Likert scales. Experiences with current and previous orthotic devices were compared. Falls were analyzed both with and without outliers. FINDINGS: 21 individuals who had used a MP-SSCO for an average duration of two years participated. Fourteen patients had prior experience with a traditional KAFO orthosis. Among them, 78.6% recalled experiencing falls, with a combined annual frequency of 67.9 (SD=167.0, Median=12.0) events. After excluding the two outliers (624 and 182 falls), a mean of 12.1 falls per patient per year was reported (range: 0 to 54, SD=15.9, Median=8.5). With the MP-SSCO, only 42.7% reported falls with an annual frequency of 5.3 (SD=17.0, Median=0.0) falls (p<0.01). After excluding outliers for MP-SSCO users, the average number of falls was 0.5 per year (range 0 to 3, SD=0.9, Median=0.0). This value was significantly lower compared to the previous orthosis (p<0.01). With their previous KAFO, 57.1% of the participants reported being able to walk downstairs, 14.3% to descend stairs with reciprocal gait, and 42.9% to vary their walking speeds. In contrast, 90.5% of MP-SSCO users reported being capable of descending stairs, 81.0% reported to descend stairs with reciprocal gait (p<0.01), and 76.2% claimed they had the ability to walk with varying speeds (p=0.03). Additionally, 71.4% of the respondents experienced an improvement in their engagement in activities with the MP-SSCO. 50.0% reported pain with the previous orthosis, compared to 38.1% with the MP-SSCO. Pain intensity was higher for the previous orthosis use (3.8) compared to MP-SSCO use (2.8) on a 1-5 scale (p=0.06). 93.3% of the participants regarded the MP-SSCO as superior, noting an enhanced quality of life (QoL) compared to the previous orthosis. CONCLUSION: Advanced orthotic technology may positively impact outcomes such as fall frequency, activities of daily living, fear of falling and pain. However, in this study, results from the previous orthosis use might have been influenced by recall bias. Layman's Abstract People with an unstable knee due to nerve and muscle problems who wear orthotic devices frequently deal with issues including pain, falls, difficulty moving around, and being unable to participate in activities. We wanted to see how much these burdens affect people who used a traditional knee-ankle-foot orthosis and compare it to a newer type of brace with advanced technology. People who had been using a new microprocessor controlled device (product: C-Brace) for at least 6 months were invited to answer questions online about how they are doing with the new brace. They rated items like how they feel and their experiences with different braces. Twenty-one people who had been using the C-Brace for an average of about 2 years participated. Fourteen had used a traditional brace before. Most of them remembered falling more often with the previous brace than with the microprocessor controlled device. With the previous brace, not many could walk downstairs easily or at all, but with the C-Brace, most could. Many also said they felt less pain with the C-Brace. People with knee problems due to nerve and muscle issues have a hard time moving around and can experience falls when they use regular braces. But using newer, microprocessor controlled braces can help them move better, fall less, and feel less pain, which makes their lives better. It is important to note that results from previous use of knee-ankle-foot orthoses (KAFOs) may have been affected by memory bias. Article PDF Link: https://jps.library.utoronto.ca/index.php/cpoj/article/view/42799/32845 How To Cite: Brüggenjürgen B, Eilers L, Seidinger S, Kannenberg A, Stukenborg-Colsman C. Patients’ burden using microprocessor-stance-and-swing-control knee-ankle-foot orthoses and outcomes compared to those with prior traditional knee-ankle-foot-orthosis. Canadian Prosthetics & Orthotics Journal. 2024; Volume 7, Issue 1, No.1. https://doi.org/10.33137/cpoj.v7i1.42799 Corresponding Author: Prof. Dr. med. Bernd Brüggenjürgen, MPHHead Institute Health Services Research and Technical Orthopedics, Orthopedic Department - Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital Anna-von-Borries-Str. 1-7, 30625 Hannover, Germany.Tel.: +49 (511) 5354 821E-Mail: brueggenjuergen.bernd@mh-hannover.de; bernd.brueggenjuergen@diakovere.deORCID ID: https://orcid.org/0000-0002-8866-0809


  • Open Access

    House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study

    by Marek Jutel, Ludger Klimek, Hartmut Richter, Bernd Brüggenjürgen, Christian Vogelberg

    Background: The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval in Germany and therefore will be available after the scheduled completion of the TAO procedure in 2026. In general, data from clinical trials on the long‐term effectiveness of HDM AIT are rare. We evaluated real‐world data (RWD) in a retrospective, observational cohort study based on a longitudinal claims database including 60% of all German statutory healthcare prescriptions to show the long‐term effectiveness of one of these products in daily life. Aim of this analysis was to provide a per product analysis on effectiveness of mite AIT as it is demanded by international guidelines on AIT.Methods: Subjects between 5 and 70 years receiving their first (index) prescription of SCIT with a native HDM product (SCIT group) between 2009 and 2013 were included. The exactly 3:1 matched control group received prescriptions for only symptomatic AR medication (non‐AIT group); the evaluation period for up to 6 years of follow‐up ended in February 2017. Study endpoints were the progression of allergic rhinitis (AR) and asthma, asthma occurrence and time to the onset of asthma after at least 2 treatment years.Results: In total, 892 subjects (608 adults and 284 children/adolescents) were included in the SCIT group and 2676 subjects (1824 adults and 852 children/adolescents) in the non‐AIT group. During the follow‐up period after at least 2 years of SCIT, the number of prescriptions in the SCIT group was reduced by 62.8% (p < .0001) for AR medication and by 42.4% for asthma medication (p = .0003). New‐onset asthma risk was significantly reduced in the SCIT vs non‐AIT group by 27.0% (p = .0212). The asthma‐preventive effect of SCIT occurred 15 months after start of the treatment. In the SCIT group, the time to onset of asthma was prolonged compared to the non‐AIT group (p = .0010).Conclusion: In this first product based RWD analysis on SCIT with a native HDM product, patients aged 5 to 70 years benefited from AIT in the long term in terms of reduced progression of AR and asthma after at least 2 years of treatment. The effects seemed to last for up to 6 years after treatment termination. A significantly reduced risk of asthma onset was observed, starting after 15 months of treatment.


  • Ökonomische Evaluation der frühen Interdisziplinären Multimodalen Schmerztherapie allein und in Kombination mit der Ganzkörper-Elektrostimulation im Vergleich zur Standardversorgung bei Patienten mit chronischen nicht-spezifischen Rückenschmerzen

    by Bernd Brüggenjürgen, Bettina Hamann, Christina Stukenborg-Colsman, Friederike Schulz

    Therapiereresistente chronische nicht-spezifische Rückenschmerzen sollen frühzeitig mit einer Interdisziplinären Multimodalen Schmerztherapie behandelt werden. Eine aktivierende Ganzkörper-Elektrostimulation ist ggf. als Vorstufe eine Alternative für ausgewählte Patienten. Kosten und Nutzen wurden mit einer Markov-Modellierung aus Sicht der deutschen Privaten Krankenversicherung untersucht. Die diskontierten 1- und 5-Jahreskosten betrugen 8,258/32,580€ für die Standardversorgung, 9,300/31,2197€ für die frühe Multimodale Schmerztherapie allein und 8,157/30,055€ für die Kombination mit der Ganzkörper-Elektrostimulation. Die kumulierten diskontierten Nutzwerte beliefen sich entsprechend auf 0,64/3,23, 0,70/3,38 und 0,69/3,37 QALYs. Multimodale Schmerztherapie allein und die Kombination mit aktivierender Ganzkörper-Elektrostimulation sind der Standardversorgung gesundheitsökonomisch überlegen. Chronic non-specific low back pain resistant to therapy should be treated early with an interdisciplinary multimodal pain management in accordance with German guidelines. An activating whole-body electrostimulation may be an alternative pain management as a precursor for selected patients. Costs and benefits were examined from the perspective of the German private health insurance using a Markov modeling. The discounted 1- and 5-year costs were 8,258/32,580€ for standard of care, 9,300/31,2197€ for early multimodal pain therapy alone, and 8,157/30,055€ for the combination with whole-body electrostimulation. The cumulative discounted utility values were 0,64/3.23, 0,70/3,38, and 0,69/3,37 QALYs, respectively. Multimodal pain therapy alone and in combination with whole-body electrostimulation in an activating physiotherapeutic setting are health-economically superior to standard of care. Article published online: 08 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Real‐world evidence for the long‐term effect of allergen immunotherapy: Current status on database‐derived European studies

    by Christian Vogelberg, Ludger Klimek, Bernd Brüggenjürgen, Marek Jutel

    Randomized controlled trials (RCTs) are the gold‐standard for benefit–risk assessments during drug approval processes. Real‐word data (RWD) and the resulting real‐world evidence (RWE) are becoming increasingly important for assessing the effectiveness of drug products after marketing authorization showing how RCT results are transferred into real life care. The effectiveness of allergen immunotherapy (AIT) has been assessed in several RWE studies based on large prescription databases. We performed a literature search for retrospective cohort assessments of prescription databases in Europe to provide an overview on the methodology, long‐term effectiveness outcomes, and adherence to AIT. Thirteen respective publications were selected. AIT was more effective in reducing the progression of allergic rhinitis (AR) compared to a non‐AIT control group receiving only symptomatic treatment for AR for up to 6 years. The development and progression of asthma were hampered for most endpoints in patients treated with most preparations compared to the non‐AIT group, receiving only anti‐asthmatic medication. The results for “time to onset” of asthma were inconsistent. Adherence to AIT decreased during the recommended 3‐year treatment period, however, in most studies higher adherence to subcutaneous than to sublingual AIT was shown. The analysis of long‐term effectiveness outcomes of the RWE studies based on prescription databases confirms the long‐term efficacy of AIT demonstrated in RCTs. Progression of rhinitis and asthma symptoms as well as delayed onset of asthma triggered by different allergens, real life adherence to the treatment shows differences in particular application routes.


  • Open Access

    EXPERTS’ PERCEIVED PATIENT BURDEN AND OUTCOMES OF KNEE-ANKLE-FOOT-ORTHOSES (KAFOs) VS. MICROPROCESSOR-STANCE-AND-SWING-PHASE-CONTROLLED-KNEE-ANKLE-FOOT ORTHOSES (MP-SSCOs)

    by Bernd Brüggenjürgen, Frank Braatz, Bernhard Greitemann, Heiko Drewitz, Axel Ruetz, Michael Schäfer, Wolfgang Seifert, Friedemann Steinfeldt, Claudia Weichold, Daiwei Yao, et al.

    BACKGROUND: Patients with neuromuscular knee-instability assisted with orthotic devices experience problems including pain, falls, mobility issues and limited engagement in daily activities. OBJECTIVES: The aim of this study was to analyse current real-life burden, needs and orthotic device outcomes in patients in need for advanced orthotic knee-ankle-foot-orthoses (KAFOs). METHODOLOGY: An observer-based semi-structured telephone interview with orthotic care experts in Germany was applied. Interviews were transcribed and content-analysed. Quantitative questions were analysed descriptively. FINDINGS: Clinical experts from eight centres which delivered an average of 49.9 KAFOs per year and 13.3 microprocessor-stance-and-swing-phase-controlled-knee-ankle-foot orthoses (MP-SSCOs) since product availability participated. Reported underlying conditions comprised incomplete paraplegia (18%), peripheral nerve lesions (20%), poliomyelitis (41%), post-traumatic lesions (8%) and other disorders (13%). The leading observed patient burdens were “restriction of mobility” (n=6), followed by “emotional strain” (n=5) and “impaired gait pattern” (n=4). Corresponding results for potential patient benefits were seen in “improved quality-of-life” (n=8) as well as “improved gait pattern” (n=8) followed by “high reliability of the orthosis” (n=7). In total, experts reported falls occurring in 71.5% of patients at a combined annual frequency of 7.0 fall events per year when using KAFOs or stance control orthoses (SCOs). In contrast, falls were observed in only 7.2 % of MP-SSCO users. CONCLUSION: Advanced orthotic technology might contribute to better quality of life of patients, improved gait pattern and perceived reliability of orthosis. In terms of safety a substantial decrease in frequency of falls was observed when comparing KAFO and MP-SSCO users. Layman's Abstract Patients who are not able to control the muscles of their legs may need to wear a brace to improve their ability to walk. However, some users are reporting problems including pain, falls, mobility issues and limited engagement in daily activities. The aim of this study was to analyse current real-life burden, needs and experiences of patients who need to wear a brace for their knee, ankle and foot (KAFO). Therefor, experts were interviewed via telephone with a structured set of questions. Eight experts provided observations for patients who suffered from several diseases affecting leg muscle control. The leading patient burdens were identified as “restriction of mobility”, followed by “emotional strain” and “impaired way of walking”. Potential patient benefits were seen in “improved quality-of-life” as well as “improved way of walking” followed by a “high trust in the brace”. Experts reported a higher number of falls per year when using KAFO without the active control of a microprocessor. On a long-term basis, experts observed consequences of KAFO use as disorders of the back, reduced amount of muscles as well as swelling in areas not covered by the brace, scrub marks and degenerative impact on joints. Braces with active control of a microprocessor might result in better quality of life of patients, improved normal way of walking and perceived trust in the brace. Article PDF Link: https://jps.library.utoronto.ca/index.php/cpoj/article/view/37795/29114 How To Cite: Brüggenjürgen B., Braatz F., Greitemann B., Drewitz H., Ruetz A., Schäfer M., et al. Experts’ perceived patient burden and outcomes of knee-ankle-foot-orthoses (KAFOs) vs. microprocessor-stance-and-swing-phase-controlled-knee-ankle-foot orthoses (MP-SSCOs). Canadian Prosthetics & Orthotics Journal. 2022; Volume 5, Issue 1, No.7.https://doi.org/10.33137/cpoj.v5i1.37795 Corresponding Author: Prof. Dr. med. Bernd Brüggenjürgen,Head Institute Health Services Research and Technical Orthopedics, Orthopedic Department - Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital, Anna-von-Borries-Str. 1-7, 30625 Hannover, Germany. E-Mail:brueggenjuergen.bernd@mh-hannover.de ORCID ID:https://orcid.org/0000-0002-8866-0809


  • Open Access

    Real world effectiveness and cost consequences of grass pollen SCIT compared with SLIT and symptomatic treatment

    by Bernd Brüggenjürgen, Ludger Klimek, Thomas Reinhold

    Purpose: Real-world evidence (RWE) with regard to allergen-specific immunotherapy (AIT) adherence is increasingly available. Economic modelling has already shown AIT to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment. However, analyzing sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches based on RWE adherence data are not available for Germany. This analysis outlines the cost-effectiveness of SCIT compared with SLIT as well as a symptomatic treatment modality on the basis of recent RWE adherence data. Methods: A Markov model, with predefined disease stages and a time period of 9 years, was adapted for this analysis. A 6-grass subcutaneous allergoid SCIT preparation and a 5-grass pollen SLIT tablet was employed as AIT administrations. Quality-adjusted life years (QALYs) were calculated based on symptom scores and used as the effectiveness variable. Total costs and cost effectiveness of SCIT, SLIT and symptomatic treatment (ST) were calculated. Model uncertainties were estimated by means of additional sensitivity analyses. Applied discount rate was 3%. Results: Both SCIT and SLIT preparations proved superior compared to symptomatic treatment with regard to effectiveness. Although more expensive, AIT also proved to be cost-effective. A direct comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed lower total costs for SCIT treatment over the study period of 9 years (SCIT 1779 € versus SLIT 2438 €) and improved effectiveness (SCIT 7.17 QALYs versus SLIT 7.11 QALYs). Conclusion: AIT represents a cost-effective treatment option for patients with allergic rhinitis compared with symptomatic treatment. SCIT appeared to be dominant and cost-effective, due in particular to higher patient adherence and lower drug costs.


  • Open Access

    Impact of public health interventions to curb SARS-CoV-2 spread assessed by an evidence-educated Delphi panel and tailored SEIR model

    by Bernd Brüggenjürgen, Hans-Peter Stricker, Lilian Krist, Miriam Ortiz, Thomas Reinhold, Stephanie Roll, Gabriele Rotter, Beate Weikert, Miriam Wiese-Posselt, Stefan N. Willich

    Aim: To use a Delphi-panel-based assessment of the effectiveness of different non-pharmaceutical interventions (NPI) in order to retrospectively approximate and to prospectively predict the SARS-CoV-2 pandemic progression via a SEIR model (susceptible, exposed, infectious, removed). Methods: We applied an evidence-educated Delphi-panel approach to elicit the impact of NPIs on the SARS-CoV-2 transmission rate R0 in Germany. Effectiveness was defined as the product of efficacy and compliance. A discrete, deterministic SEIR model with time step of 1 day, a latency period of 1.8 days, duration of infectiousness of 5 days, and a share of the total population of 15% assumed to be protected by immunity was developed in order to estimate the impact of selected NPI measures on the course of the pandemic. The model was populated with the Delphi-panel results and varied in sensitivity analyses. Results: Efficacy and compliance estimates for the three most effective NPIs were as follows: test and isolate 49% (efficacy)/78% (compliance), keeping distance 42%/74%, personal protection masks (cloth masks or other face masks) 33%/79%. Applying all NPI effectiveness estimates to the SEIR model resulted in a valid replication of reported occurrence of the German SARS-CoV-2 pandemic. A combination of four NPIs at consented compliance rates might curb the CoViD-19 pandemic. Conclusion: Employing an evidence-educated Delphi-panel approach can support SARS-CoV-2 modelling. Future curbing scenarios require a combination of NPIs. A Delphi-panel-based NPI assessment and modelling might support public health policy decision making by informing sequence and number of needed public health measures.